Evidence map›Paper›PMID 26164827›Full record

ArticleAmerican journal of ophthalmology2015

Multimodal Imaging of Central Retinal Disease Progression in a 2-Year Mean Follow-up of Retinitis Pigmentosa.

Tharikarn Sujirakul, Michael K Lin, Jimmy Duong, Ying Wei, Sara Lopez-Pintado, Stephen H Tsang

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05537220 (NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05537220 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2030Enrolled485ConditionsRetinitis PigmentosaArmsN-acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Long-term natural history of ellipsoid zone width inThe British journal of ophthalmology · 2025
    Article
  15. OCT Biomarkers in a Cohort of Patients WithJournal of ophthalmology · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Observational

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Tharikarn SujirakulBernard & Shirlee Brown Glaucoma Laboratory and Barbara & Donald Jonas Stem Cell Laboratory, Department of Ophthalmology, Columbia University, New York, New York; Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Michael K LinCollege of Physicians & Surgeons, Columbia University, New York, New York.
Jimmy DuongDepartment of Biostatistics, Columbia University, New York, New York.
Ying WeiDepartment of Biostatistics, Columbia University, New York, New York.
Sara Lopez-PintadoDepartment of Biostatistics, Columbia University, New York, New York.
Stephen H TsangBernard & Shirlee Brown Glaucoma Laboratory and Barbara & Donald Jonas Stem Cell Laboratory, Department of Ophthalmology, Columbia University, New York, New York; Department of Pathology and Cell Biology and Institute of Human Nutrition, Columbia University, New York, New York. Electronic address: sht2@columbia.edu.
Columbia University · USRamathibodi Hospital · TH

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Instrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9M
Toward mechanism- and gene-based therapies for retinal degenerationR01EY018213 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2008 to 2026
$6.6M
Evaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS CellsR21AG050437 · NIA · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G, MAHAJAN, VINIT B · 2015 to 2016
$431k
NCI NIH HHS 5P30CA013696NCI NIH HHS P30 CA013696NEI NIH HHS 5P30EY019007NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY018213NEI NIH HHS R01EY018213NIA NIH HHS R21 AG050437NIA NIH HHS R21AG050437
6 · The paper itself

Abstract

purposeTo determine the rate of progression and optimal follow-up time in patients with advanced-stage retinitis pigmentosa (RP) comparing the use of fundus autofluorescence imaging and spectral-domain optical coherence tomography.

designRetrospective analysis of progression rate.

methodsLongitudinal imaging follow-up in 71 patients with retinitis pigmentosa was studied using the main outcome measurements of hyperautofluoresent ring horizontal diameter and vertical diameter along with ellipsoid zone line width from spectral-domain optical coherence tomography. Test-retest reliability and the rate of progression were calculated. The interaction between the progression rates was tested for sex, age, mode of inheritance, and baseline measurement size. Symmetry of left and right eye progression rate was also tested.

resultsSignificant progression was observed in >75% of patients during the 2-year mean follow-up. The mean annual progression rates of ellipsoid zone line and hyperautofluorescent ring horizontal diameter and vertical diameter were 0.45 degree (4.9%), 0.51 degree (4.1%), and 0.42 degree (4.0%), respectively. The ellipsoid zone line width and hyperautofluorescent ring horizontal diameter and vertical diameter had low test-retest variabilities of 8.9%, 9.5%, and 9.6%, respectively. This study is the first to demonstrate asymmetrical structural progression rate between right and left eye, which was found in 19% of patients. The rate of progression was significantly slower as the disease approached the fovea, supporting the theory that RP progresses in an exponential fashion. No significant interaction between progression rate and patient age, sex, or mode of inheritance was observed.

conclusionsFundus autofluorescence and optical coherence tomography detect progression in patients with RP reliably and with strong correlation. These parameters may be useful alongside functional assessments as the outcome measurements for future therapeutic trials. Follow-up at 1-year intervals should be adequate to efficiently detect progression.

Indexed as

AdolescentAdultAgedAged, 80 and overChildDisease ProgressionElectroretinographyFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleMiddle AgedMultimodal ImagingRetinaRetinal Photoreceptor Cell Outer Segment

Identifiers

PMID26164827
PMCPMC4754981
OpenAlexW2149458881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.